Abstract:Berberine is a natural plant alkaloid isolated from a diverse range of genera, it obtains anti-inflammatory, anti-obesity, and hepatoprotective properties, and is a promising agent for non-alcoholic steatohepatitis (NASH). Farnesoid X receptor (FXR) is a bile acid receptor and a drug target for NASH, however, the underlying mechanisms of berberine on regulating FXR are still unknown. In the present study, we feed mice with a 12-week high-fat diet with interval dextran sulfate sodium (0.5% in drinking water) diet to induce NASH, and treat the mice with berberine (100 mg/kg per day) via oral gavage for additional 4 weeks. We demonstrate that administration of berberine alleviates steatosis and infiltration of inflammatory cells in the liver of NASH mice. We apply 16S ribosomal DNA sequencing to screen the structure of gut microbiota, and ultra-performance liquid chromatography-tandem mass spectrometry analysis to determine the bile acid profiles. The results show that berberine modulates gut dysbiosis, and specifically increases the relative abundance of Clostridiales , Lactobacillaceae, and Bacteroidale . Berberine modulated microbiomes are associated with bile acid de-conjugation and transformation, which are consistent with the altered bile acid species (e.g., deoxycholic acid, ursodeoxycholic acid) upon berberine treatment. BA species that respond to berberine treatment are known FXR agonists, thus we performed quantitative Real Time-PCR and western blot to examine the FXR pathway, and find that berberine up-regulates intestinal FXR and fibroblast growth factor 15 (FGF15) expression, and the secretion of FGF15 further inhibits lipogenesis and nuclear factor-κB activation in the liver. Whereas the beneficial effects of berberine are blunted in FXR knockout mice. Our results reveal that berberine alleviates NASH by modulating the interplay of gut microbiota and bile acid metabolism, as well as the subsequent intestinal FXR activation.

Demethylenetetrahydroberberine Alleviates Nonalcoholic Fatty Liver Disease by Inhibiting the NLRP3 Inflammasome and Oxidative Stress in Mice

Demethyleneberberine Attenuates Non-Alcoholic Fatty Liver Disease with Activation of AMPK and Inhibition of Oxidative Stress.

Demethyleneberberine Attenuates Free Fatty Acid- And High Fat Diet-Induced Hepatic Lipotoxicity By Activating AMP-Activated Protein Kinase

Protective Effects of Berberine on Nonalcoholic Fatty Liver Disease in db/db Mice via AMPK/SIRT1 Pathway Activation

Berberine Alleviates Nonalcoholic Fatty Liver Induced by a High-Fat Diet in Mice by Activating SIRT3.

Betaine Alleviates Nonalcoholic Fatty Liver Disease (NAFLD) Via a Manner Involving BHMT/FTO/m6A/ PGC1α Signaling.

Demethyleneberberine, a Natural Mitochondria-Targeted Antioxidant, Inhibits Mitochondrial Dysfunction, Oxidative Stress, and Steatosis in Alcoholic Liver Disease Mouse Model.

Dihydromyricetin Alleviates Nonalcoholic Fatty Liver Disease and Its Associated Metabolic Syndrome by Inhibiting Endoplasmic Reticulum Stress in LDLR−/− Mice Fed with a High-Fat and High-Fructose Diet

Berberine Reduces Methylation of the MTTP Promoter and Alleviates Fatty Liver Induced by a High-Fat Diet in Rats

Berberine Ameliorates Nonalcoholic Fatty Liver Disease by A Global Modulation of Hepatic Mrna and Lncrna Expression Profiles

Anti-inflammatory activity of berberine in non-alcoholic fatty liver disease via the Angptl2 pathway

Demethyleneberberine Protects against Hepatic Fibrosis in Mice by Modulating NF-κB Signaling.

Efficacy of Berberine in Patients with Non-Alcoholic Fatty Liver Disease

Demethyleneberberine Protects Against Hepatic Fibrosis in Mice by Modulating NF-κB Signaling

Combined Use of Bicyclol and Berberine Alleviates Mouse Nonalcoholic Fatty Liver Disease

Berberine Ameliorates Hepatic Steatosis and Suppresses Liver and Adipose Tissue Inflammation in Mice with Diet-induced Obesity

Dihydromyricetin Ameliorates Nonalcoholic Fatty Liver Disease by Improving Mitochondrial Respiratory Capacity and Redox Homeostasis Through Modulation of SIRT3 Signaling

Berberine prevents progression from hepatic steatosis to steatohepatitis and fibrosis by reducing endoplasmic reticulum stress

Demethyleneberberine Alleviates Inflammatory Bowel Disease in Mice Through Regulating NF-κB Signaling and T-helper Cell Homeostasis

Berberine Alleviates Non-alcoholic Steatohepatitis Through Modulating Gut Microbiota Mediated Intestinal FXR Activation

Berberine Ameliorates High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease in Rats Via Activation of SIRT3/AMPK/ACC Pathway